ArticleMedicine2026
Epidemiology of metabolic dysfunction-associated steatotic liver disease and discordance in non-invasive fibrosis scores in Eastern China: A cross-sectional study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The contemporary epidemiology of metabolic dysfunction-associated steatotic liver disease (MASLD) and the risk stratification provided by noninvasive tests (NITs) for fibrosis in large populations require further characterization. Specifically, the degree of agreement between different NITs and how their association with metabolic comorbidities varies in Chinese MASLD cohorts remains unclear. This study aimed to systematically evaluate the prevalence of MASLD and to compare the performances among 3 NITs for fibrosis in a large eastern Chinese cohort. In this cross-sectional study, which included 201,616 adults from eastern China between January 01, 2021 and March 31, 2025, MASLD was diagnosed based on hepatic steatosis on ultrasonography plus metabolic criteria according to the latest guidelines. Liver fibrosis was assessed using the FIB-4 index, nonalcoholic fatty liver disease fibrosis score (NFS), and aspartate transaminase to platelet ratio index (APRI). Sex-and age-standardized prevalence was calculated. Associated factors were analyzed via multivariable logistic regression. The standardized prevalence of MASLD was 39.42%, higher in males (49.98%) than females (28.59%), with obesity as the strongest risk factor (aOR: 7.69). Among MASLD patients, significant fibrosis prevalence was similar when assessed by FIB-4 (19.12%) and NFS (21.32%); advanced fibrosis was lowest according to APRI (0.61%) compared to FIB-4 (1.79%) and NFS (1.97%). Critically, the associations between metabolic comorbidities (e.g., diabetes, dyslipidemia) and fibrosis risk varied substantially depending on the NIT used. MASLD is highly prevalent in this eastern Chinese health checkup cohort. The marked discordance in fibrosis risk stratification across different NITs, particularly in patients with metabolic comorbidities, highlights that these tools provide complementary rather than interchangeable information. These findings suggest the need for cautious interpretation of NIT results and further research into context-aware risk stratification strategies that consider both the specific NIT employed and the patient's metabolic profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.